Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,395 INR
Change Today +15.55 / 1.13%
Volume 4.0K
CLPL On Other Exchanges
Symbol
Exchange
CLPL is not on other exchanges.
As of 12:11 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

caplin point laboratories (CLPL) Snapshot

Open
1,410
Previous Close
1,379
Day High
1,432
Day Low
1,383
52 Week High
08/21/15 - 1,523
52 Week Low
10/13/14 - 315.00
Market Cap
21.1B
Average Volume 10 Days
79.1K
EPS TTM
27.16
Shares Outstanding
15.1M
EX-Date
--
P/E TM
51.4x
Dividend
5.00
Dividend Yield
0.29%
Current Stock Chart for CAPLIN POINT LABORATORIES (CLPL)

Related News

No related news articles were found.

caplin point laboratories (CLPL) Related Businessweek News

No Related Businessweek News Found

caplin point laboratories (CLPL) Details

Caplin Point Laboratories Limited manufactures and sells pharmaceutical formulations in India and internationally. Its product portfolio includes analgesic and antipyretic, antacid, anthelmintic, anti-amoebic, anti-bacterials, antibiotic, anti-cold, antihistaminic, anti-diabetic, anti-hypertensive and anti-anginal, anti-malarial, and antirheumatic formulations. The company’s product line also comprises anti-spasmodic, anti-tubercular, anti-viral, bronchodilator, cortisone, cough syrup, diuretic, haematinic, oral rehydration salts, ointments and gels, urinary antibacterial, and vitamin supplements. In addition, it offers novel and special products, biotech and other lyophilized products, effervescent tablets, soft gel capsules, and medical and hospital consumables, as well as provides contract manufacturing services. Further, the company manufactures a range of creams and other external application products. Caplin Point Laboratories Limited was founded in 1990 and is based in Chennai, India.

Founded in 1990

caplin point laboratories (CLPL) Top Compensated Officers

Managing Director, Compliance Officer, Execut...
Total Annual Compensation: 588.4K
Chief Operating officer
Total Annual Compensation: 1.8M
Whole Time Director, Member of Audit Committe...
Total Annual Compensation: 633.4K
Compensation as of Fiscal Year 2014.

caplin point laboratories (CLPL) Key Developments

Caplin Point Laboratories Ltd. Announces Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015

Caplin Point Laboratories Ltd. announced audited standalone and consolidated earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, on consolidated basis, the company reported gross revenue of INR 701.3 million against INR 480.1 million a year ago. EBITDA was INR 197.0 million against INR 104.7 million a year ago. PAT was INR 126.9 million against INR 69.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 156.806 million compared to INR 80.111 million a year ago. Profit from ordinary activities before tax was INR 164.955 million compared to INR 88.135 million a year ago. Net profit after minority interest was INR 126.893 million or INR 8.40 per basic and diluted share before and after extraordinary items compared to INR 69.823 million or INR 4.62 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported gross revenue of INR 2,517.7 million against INR 1,730.9 million a year ago. EBITDA was INR 620.0 million against INR 393.5 million a year ago. PAT was INR 410.4 million against INR 258.5 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 505.897 million compared to INR 320.943 million a year ago. Profit from ordinary activities before tax was INR 533.887 million compared to INR 356.908 million a year ago. Net profit after minority interest was INR 410.369 million or INR 27.16 per basic and diluted share before and after extraordinary items compared to INR 258.486 million or INR 17.11 per basic and diluted share before and after extraordinary items a year ago. For the quarter, on standalone basis, the company reported gross revenue of INR 675.518 million against INR 459.315 million a year ago. EBITDA was INR 193.6 million against INR 99.1 million a year ago. PAT was INR 127.0 million against INR 69.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 154.335 million compared to INR 76.425 million a year ago. Profit from ordinary activities before tax was INR 161.790 million compared to INR 82.763 million a year ago. Net profit for the period was INR 126.968 million or INR 8.40 per basic and diluted share before and after extraordinary items compared to INR 69.263 million or INR 4.58 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported gross revenue of INR 2,402.3 million against INR 1,664.0 million a year ago. EBITDA was INR 593.0 million against INR 369.4 million a year ago. PAT was INR 409.4 million against INR 256.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 482.817 million compared to INR 301.606 million a year ago. Profit from ordinary activities before tax was INR 507.987 million compared to INR 333.794 million a year ago. Net profit for the period was INR 409.356 million or INR 27.09 per basic and diluted share before and after extraordinary items compared to INR 256.354 million or INR 16.97 per basic and diluted share before and after extraordinary items a year ago.

Caplin Point Laboratories Ltd Recommends Dividend for the Year Ended June 30, 2015

Caplin Point Laboratories Ltd. at its board meeting held on August 20, 2015, recommended a dividend of INR 5 (50%) per equity share of INR 10 each (fully paid up) for the financial year ended June 30, 2015, subject to approval of shareholders.

Caplin Point Laboratories Ltd to Report Fiscal Year 2015 Results on Aug 20, 2015

Caplin Point Laboratories Ltd announced that they will report fiscal year 2015 results on Aug 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLPL:IN 1,395.00 INR +15.55

CLPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLPL.
View Industry Companies
 

Industry Analysis

CLPL

Industry Average

Valuation CLPL Industry Range
Price/Earnings 49.1x
Price/Sales 8.0x
Price/Book 21.6x
Price/Cash Flow 40.8x
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPLIN POINT LABORATORIES, please visit www.caplinpoint.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.